The omega-3 EPA:DHA 6:1 formulation prevents the monocrotaline-induced pulmonary hypertension, pulmonary artery remodelling, endothelial dysfunction, and right ventricular failure in rats
XX
BSO - Titre
O40 The omega-3 EPA:DHA 6:1 formulation prevents the monocrotaline-induced pulmonary hypertension, pulmonary artery remodelling, endothelial dysfunction, and right ventricular failure in rats